[Skip to Content]
[Skip to Content Landing]
Views 535
Citations 0
Comment & Response
November 7, 2017

Alendronate and Hip Fracture in Patients Using Glucocorticoids

Author Affiliations
  • 1Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham & Women’s Hospital, Boston, Massachusetts
JAMA. 2017;318(17):1711-1712. doi:10.1001/jama.2017.14291

To the Editor Dr Axelsson and colleagues1 evaluated the association between alendronate use and risk of hip fracture among older adults taking prednisolone. Although the availability of a large population-based cohort is a major strength, their study design comparing prevalent alendronate users with nonusers raises several concerns.

First, treated patients were required to have at least 3 months of alendronate use and evidence of current use at the start of follow-up for outcomes. Therefore, alendronate users who experienced safety events early in the treatment course and discontinued treatment because of the adverse event would not have been eligible for inclusion in this study. This could have resulted in underestimation of safety events due to depletion of susceptible patients from the treatment group.2,3

First Page Preview View Large
First page PDF preview
First page PDF preview
×